NCT07126236
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07126236
Title Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma (REPIFIR)
Acronym REPIFIR
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Grupo Espanol de Linfomas y Transplante Autologo de Medula osea
Indications
Therapies
Age Groups: adult | senior
Covered Countries ESP


No variant requirements are available.